Contributors

The editors of the MiMe PinPoint Case Platform thank the expert contributors of the multidisciplinary disease expert panels.
The editors select the disease panel members based on two principal criteria: 1. extensive scientific output and 2. considerable clinical experience within the subject disease area. In addition, a reasonable geographic spread of the contributors is sought. Experts may serve multiple topics in their expertise disease area.

Antonio Alcaraz

Antonio Alcaraz

University of Barcelona, Urology

Barcelona, Spain

Disease area: Prostate cancer

Biography:
Antonio Alcaraz is Professor of Surgery at the University of Barcelona, Spain. He received his medical degree in 1983, and his PhD in 1987, both from the University of Barcelona. After a 5 year residency in urology at the University Hospital Clinic in Barcelona, he became a member of the Spanish Board of Urology in 1988. He completed a research fellowship at the Mayo Clinic in Rochester, USA between 1993 and 1994. Professor Alcaraz was Head of the Transplant and Oncology Unit of the Department of Urology at Fundacio Puigvert between 2002 and 2005. Since February 2005, he has been Chair of the Department of Urology at the University Hospital Clinic of Barcelona, and was Chair of the Transplant Section (2004-2008) and then Secretary General of the Spanish Association of Urology (2008-2012). Professor Alcaraz’s research interests include major uro-oncological, laparoscopic and transplant surgery, being pioneer in single port surgery and transvaginal nephrectomy. Most of his translational research has been done on cancer genetics. He has authored more than 225 international and Spanish publications. He has been a member of the board of the European School of Urology, and member of the Scientific Committee of the European Association of Urology (2010-2016).

See COI

Amit Bahl

Amit Bahl

Bristol Haematology & Oncology Centre, Radiotherapy

Bristol, United Kingdom

Disease area: Prostate cancer

Biography:
Amit Bahl is Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol and Clinical Director of Spire Specialist Care Centre with a special interest in breast and urological cancers. He is the research lead for Uro-oncology at Bristol Cancer Institute, and led and developed the prostate brachytherapy service in Bristol. He has been an expert adviser to NICE for the technology appraisal on new drugs and an external service reviewer at oncology departments elsewhere in the country. He has more than 100 peer reviewed publications. Dr Bahl trained in Clinical Oncology, achieving Fellowship of the Royal College of Radiologists, and has been elected as a fellow of the Royal College of Physicians. Currently, he is a member of the National Cancer Research Institute Clinical Studies Groups for bladder cancer, and chairs the penile cancer subgroup. He is also an Executive Committee member of the British Uro-oncology group. In 2012, Dr Bahl was awarded the Cochrane Shanks Jalil Professorship by the Royal College of Radiologists, London, and he is Visiting Professor to two international centres and at University of West of England.

See COI

Anders Bjartell

Anders Bjartell

Lund University, Clinical Sciences

Lund, Sweden

Disease area: Prostate cancer

Biography:
Anders Bjartell MD, PhD FEBU graduated from Lund University Medical School, Sweden, in 1986. He was a research fellow at the National Institutes of Health in Bethesda, Maryland, USA, from 1988 to 1989, and received his PhD in Medical Cell Research from Lund University in 1990. After training at the University Hospital in Malmö, he became Specialist in Urology in 1998, and received his Fellows of the European Board of Urology (FEBU) diploma in 1999. He was appointed Associate Professor at Lund University in 1995. Professor Bjartell was a Clinical Investigator at the Department of Urology, Memorial Sloan Kettering Cancer Center in New York, USA, from 2005 to 2007, Associate Editor for European Urology from 2005 to 2012, and he is past-president and board member of the European Association of Urology (EAU) Section of Urological Research (ESUR) and board member of EAU Guidelines Office. Professor Bjartell was appointed Chairman of the EAU Research Foundation in 2017 and since 2016 he is Board member of the EAU Guidelines Office. In 2006, Professor Bjartell became full Professor in Clinical Urology, and Senior Consultant at Skåne University Hospital in Malmö. In 2012, he was appointed Assistant Dean at the Medical Faculty, Lund University. Professor Bjartell is also a national principal investigator for several trials of new drugs in castration resistant prostate cancer and Head of the clinical trial unit at the Urology Department at Skåne University Hospital. He leads a research group in translational prostate cancer research with long term experience in prostate cancer biomarkers. His research also encompasses clinical projects on robotic surgery, imaging, and drug development. He has participated in several EU-sponsored prostate cancer projects, and he has published more than 258 peer reviewed original articles.

See COI

Bertil Blok

Bertil Blok

Erasmus University Rotterdam, Urology

Rotterdam, Netherlands

Disease area: Lower Urinary Tract Dysfunction

Biography:
Dr Blok was born and raised in the Netherlands. He received his MD cum laude from the Erasmus Medical Center in Rotterdam in 1990. Because of an interest in neuroscience, he moved to the University of Groningen where he subsequently worked as an assistant Professor, and a Lecturer at the Department of Anatomy at the University of Groningen. He completed his PhD cum laude at this department on the central control of the urinary bladder. From 2000 to 2006 he was resident in Urology at the Academic Medical Center in Amsterdam and McGill University in Montreal. In 2006, he was fellow of the Canadian Institutes for Health Research on Urogynaecology and stem cell research and was awarded a staff position at the Urology department of McGill University. From November 2006 he is staff urologist at the Erasmus Medical Center in Rotterdam. In that position he is director of the Erasmus Pelvic Care Center, Medical Coordinator of the Urology outpatient clinic, consultant at the Rijndam Rehabilition center and coordinator of the Functional Urology subdivision. Among other positions he is chair of the European Guidelines Committee for Neuro-Urology and member of the editorial board of the Dutch Journal of Urology.

Alberto Bossi

Alberto Bossi

Gustave Roussy Institute, Radiation oncology

Villejuif, France

Disease area: Prostate cancer

Biography:
Dr Alberto Bossi is currently Head of the Urology and Prostate Brachytherapy Unit at the Gustave Roussy Cancer Institute in Villejuif, France. His professional career started in Italy where he was born: he graduated in Medicine and Surgery in 1988 and specialized in Radiotherapy and Diagnostic Radiology in 1992 at the University of Pavia. After a Clinical Fellowship at the Dept of Radiation Oncology at the Academic Medical Centre in Amsterdam he worked in Como and Milan. In 2001 he was appointed Adjunct Clinical Head at the Department of Radiation Oncology of the University Hospital in Leuven, Belgium where he worked till 2006 before moving to IGR. Dr Bossi is member of several scientific societies, including ESTRO, ASTRO, EAU. He has served as Coordinator of the Genito-Urinary Working Group of the EORTC in 2006. He is the Course Director of the Multidisciplinary ESTRO-EAU-ESMO Teaching Course on Prostate Cancer and teacher at both the ESO (European School of Oncology) and EAU (European Association of Urology) Prostate Courses. He is PI and co-PI (Principal Investigator) of two major European Phase III trials on Prostate Cancer and has published over 40 papers in peer-reviewed journals. Dr Bossi is reviewer for several journals including the IJROBP, European Urology, Radiotherapy and Oncology, Annals of Oncology.

See COI

Dejan Bratus

Dejan Bratus

University Medical Centre Maribor, Urology

Maribor, Slovenia

Disease area: Lower Urinary Tract Dysfunction

Biography:
Dr. Bratuš was born on February 8th 1964 in Maribor, Slovenia. After finishing grade school, he continued studying on Prva Gimnazija high school in Maribor, of which he finished three years. He attended his senior high school year on Pearl River High School in Pearl River, New York, USA, where he graduated in 1982. After that he began with the study of medicine on Medical Faculty of University in Ljubljana and successfully finished it in 1991. First he completed one year of internship in General Hospital Maribor, where he also stayed to specialize in urology. He finished his training in 1997 and became an urologist. He is currently a head of the Department of Urology at the University medical center Maribor. He has attended the postgraduate study of urology on Medical Faculty of University in Zagreb, Croatia, where he successfully completed it and became a bachelor of science in 2005. He is currently preparing his PhD thesis at the Medical Faculty of University in Maribor. He is a member and current president of Slovenian Urological Association and he is also a member of European Association of Urology (EAU) and European Society for Sexual Medicine (ESSM). he has also founded a Slovenian affiliation to ESSM, Society for Sexual Medicine of Slovenia (SSMS), of which he is also currently the president. Above that he is at the moment the national coordinator of urological specialization at Medical chamber of Slovenia.

See COI

Alberto Briganti

Alberto Briganti

Vita-Salute University San Raffaele, Urology

Milan, Italy

Disease area: Prostate cancer

Biography:
Dr Briganti works as Urologist at Vita-Salute University, San Raffaele Hospital, Milan, Italy. He is a member of several national and international associations as well as being a member of the European Urology Editorial Board at Large. He is a fellow of the European Board of Urology and is also a reviewer of the main urological journals. He is author and co-author of more than 150 papers published in peer reviewed, indexed Journals. His main clinical interests are urological oncology, including development and validation of several prognostic staging tools, and sexual medicine, including erectile dysfunction and male sexual health. He has contributed to the development of several multi-institutional data-bases for prostate cancer staging and outcomes which have been used for improving currently available prediction models.

See COI

Alexandre de la Taille

Alexandre de la Taille

CHU Henri Mondor, Assistance Publique des Hopitaux de Paris, Urology

Créteil, France

Disease area: Prostate cancer

Biography:
Professor Alexandre de la Taille is head of Urology Department in CHU Mondor Assistance Publique des Hopitaux de Paris in France and also head of the Inserm U955Eq07 research team on translational research in uro-oncology. He has been involved in uro-oncology for over 15 years and is in charge of the robotic surgery program. His research and clinical activity are focused on Prostate (BPH and cancer). His main research programs include discovery and validation of biomarkers for high-risk prostate cancer patients treated by chemotherapy and hormonal therapies and in inflammation in prostatic benign hyperplasia patients. He teaches and has spoken on urology, robotic surgery and molecular biology of prostate cancer at Paris XII University, IRCAD, American Uologi- cal Association (AUA) meetings and European Association of Urology (EAU) meetings. He is one of the member of the Scientific Office of EAU. He wrote over 411 articles, predominantly focusing on prostate cancer, and his work has received an array of honors, such as the Crystal Matula Award from the EAU and the first prize of research from the American Urological Association (AUA).

See COI

Theo de Reijke

Theo de Reijke

Academic Medical Center, Urology

Amsterdam, Netherlands

Disease area: Prostate cancer

Biography:
Theo M. de Reijke performed his medical training at the Free University in Amsterdam and is working since 1987 as urologist at the Academic Medical Center in Amsterdam. In 2004 he successfully defended his thesis on immunotherapy for bladder cancer. Uro-oncology (prostate and bladder cancer) is his main field of interest and he has been an active member of the European Organization for Research and Treatment of Cancer – Genito Urinary group (EORTC-GU) for many years. After serving as chairman of the prostate cancer subgroup, he was elected as secretary and later as chairman of the EORTC-GU group until June 2009. In the Netherlands, he is the chairman of the prostate cancer guideline committee and he is member of the bladder cancer guideline committee. He is member of different international Urological societies (e.g. EAU, AUA, DGU), reviewer for several international journals and member of scientific boards for different journals. In 2011, he was elected as reviewer of the month for European Urology. He is (co-) author of over 100 publications in peer-reviewed journals and he made contributions to many book chapters. He organised several scientific national and international meetings and is/was coordinator of international uro-oncology trials.

See COI

Stefan De Wachter

Stefan De Wachter

University Hospital Antwerp, Urology

Antwerp, Belgium

Disease area: Lower Urinary Tract Dysfunction

Biography:
Prof. Dr. Stefan De Wachter is professor of Urology at the University Hospital of Antwerp and chairman of Urology in the academic Hospital Antwerpen. He is involved in the management of functional urology, neurourology, and reconstructive urology. In 2003, he obtained his PhD degree, for which he received the “EAU Thesis Award” in 2004. He serves as reviewer for many international urological journals, such as Neurourology and Urodynamics, Journal of Urology, European Urology, International Urogynaecology Journal, British Journal of Urology and Spinal Cord. He has published more than 120 papers in peer-reviewed journals, and presented at numerous national and international symposia and congresses.

See COI

David Dearnaley

David Dearnaley

The Royal Marsden NHS Foundation Trust, Uro-Oncology

Surrey, United Kingdom

Disease area: Prostate cancer

Biography:
David Dearnaley is Professor of Uro-Oncology and lead clinician in the Academic Unit of Radiotherapy at The Royal Marsden (RMH) and The Institute of Cancer Research (ICR). He was Head of RMH Urology Unit from 1994 to 2006 and Chairman of RMH/ICR Committee for Clinical Research 2006 - 2013. He is the Prostate Theme Lead for the RMH/ICR Biomedical Research Centre. He was appointed NIHR Senior Investigator in 2008 - 2015 and is a member of the NHS R&D HTA Clinical Trials Board College of Experts (2012-). He has previously chaired both the MRC and NCRI Prostate Study Groups, as well as the MRC Radiotherapy Clinical Trials Group. Principal areas of research are the development of conformal (CFRT), intensity modulated (IMRT), image-guided (IGRT) and hypofractionated radiotherapy treatments for prostate cancer. He has led phase III randomised trials to establish these in clinical practice and dose escalated CFRT has been incorporated in NICE guidance. Presently he leads associated translational programmes into the biophysics, radiogenomics and molecular pathology of radiation response and toxicity. Additionally he has a major interest in the systemic treatment of prostate cancer using hormonal therapies, chemotherapy, targeted isotopes and bone protective agents.

See COI

José Luis Domínguez-Escrig

José Luis Domínguez-Escrig

Instituto Valenciano de Oncologia, Urology

Valencia, Spain

Disease area: Prostate cancer

Biography:
Dr. José Luís Domínguez-Escrig graduated in Medicine and Surgery in July1994, in Valencia, Spain, continuing his postgraduate training in the UK. Having completed his BST obtained the Membership of the Royal College of Surgeons of England in 2001 and the Fellowship of the Royal College of Surgeons in Urology, FRSC(Urol) in 2009. From 2004 to 2006 he performed his research at the prestigious Northern Institute for Cancer Research-Newcastle University, UK. On completion of his research project, he submitted the Thesis “Tyrosine Kinase and Farnesyltarnsferase Inhibitors: Potential Selective Tailored Therapeutics in Bladder Cancer” and was awarded the Degree of Doctor of Medicine in 2006. He has published in several international peer reviewed Journals and he has reviewed articles for BJU Int, Urol Oncology and the Journal of Urology and has imparted several lectures and presented at international meetings including AACR, AUA, EAU, BAUS and AEU. He returned to Spain in 2011 and he is currently working as a Consultant Urology Surgeon at the Fundación Instituto Valenciano de Oncología (I.V.O.) in Valencia, where he combines his clinical work with an active involvement in translational research, participating as PI in several Clinical Trials in prostate and bladder cancer. Since 2015 is a systematic reviewer for the EAU NMIBC Guidelines panel and also Spanish delegate to the European Board of Urology (E.B.U.) as well as, member of the F.E.B.U. examination committee. His main interests are urothelial carcinoma NMIBC and MIBC and the evaluation and development of focal therapies in Uro-oncology.

See COI

Marcus Drake

Marcus Drake

Bristol Urological Institute, Urology

Bristol, United Kingdom

Disease area: Lower Urinary Tract Dysfunction

Biography:
Marcus Drake is Consultant Surgeon at the Bristol Urological Institute, Bristol, UK, subspecialising in Female and Reconstructive Urology, Neurourology and Urodynamics. He is Senior Lecturer in Urology at the University of Bristol, and Visiting Professor in Health and Applied Sciences at the University of the West of England. He is Chief Investigator of the national randomised trial of urodynamics in male LUTS (UPSTREAM) and a study of melatonin for nocturia in MS. He was co-ordinating investigator of the multinational studies of combination therapy for male LUTS (NEPTUNE-2) and overactive bladder (BESIDE). He leads a basic science research programme in integrative neurophysiology and functional urology. He has published over 100 research papers and reviews, a book and 20 book chapters. He is Chairman of the International Continence Society’s Standardisation Steering Committee, a board member of the European School of Urology, and of the European Society of Female and Functional Urology. He is also a member of the European Association of Urology Guidelines committee for Male LUTS. In 2012, he chaired the Neurogenic Incontinence committee at the International Consultation on Incontinence and the Nocturia committee at the Consultation on Male LUTS. He is former Chairman for Urology/ Urogynaecology in the UK National Health Service’s Comprehensive Clinical Research Network. He undertook his medical training at the Universities of Cambridge and Oxford and was awarded his Doctorate Thesis by the University of Oxford.

See COI

Karel Everaert

Karel Everaert

Ghent University Hospital, Urology

Ghent, Belgium

Disease area: Lower Urinary Tract Dysfunction

Biography:
Karel Everaert graduated in 1988 from the University of Ghent as Medical Doctor. Between 1988 and 1993 he was a training resident at several national and international hospitals. Since 1993 he is responsible for Neuro-urology, incontinence, urodynamics and male infertility in the Department of Urology, UZ Ghent. He obtained his Ph.D in 1999, with a thesis on tubular proteinuria in urinary tract infection, vesico ureteral reflux and hydronephrosis. In 2001 he was appointed Full Professor in Neuro-Urology. He has attended numerous postgraduate training courses and was involved in teaching activities in Belgium and abroad. Prof. Everaert is Fellow of the European Board of Urology. He is a respected member of several urological societies. He’s founding member of PELVIRED and board member of the BVU. Prof. Everaert is author of more than 40 articles in international journals. He is co-author of several textbooks in Urology. He has given more than 50 presentations at national and international congresses and was involved in the organisation of numerous meetings. He received several awards for his research activities.

See COI

Valérie Fonteyne

Valérie Fonteyne

Ghent University Hospital, Radiotherapy

Ghent, Belgium

Disease area: Prostate cancer

Biography:
Prof. Dr Valérie Fonteyne is a staff member at the Department of Radiotherapy-Oncology, Ghent University Hospital, Ghent, Belgium since 2003. She is member of several national and international associations. She is teacher at the ESTRO Prostate course as well as ESMO preceptorship on prostate cancer. Her research interests include urological tumours, pain management and stereotactic body radiation therapy. She (co-)authored several publications in peer reviewed, indexed journals and is co-author of 2 book chapters. Her clinical and research interest are urological oncology with a specific focus on hypofractionated radiotherapy for prostate cancer, improving the outcome of node positive prostate cancer as well as establishing the place of radiotherapy in bladder cancer. Within these domains she is principal investigator of several prospective trials.

See COI

Giorgio Gandaglia

Giorgio Gandaglia

Ospedale Vita-Salute San Raffaele, Urology

Milan, Italy

Disease area: Prostate cancer

Biography:
Giorgio Gandaglia is a Urologist at the Department of Urology, San Raffaele Hospital, Milan, Italy. He earned his MD in 2011 at the Vita-Salute University, Milan where he also pursued residency. He completed a Research Fellowship in Urologic Oncology at the Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada under the supervision of Prof. Pierre I. Karakiewicz and a fellowship at the OLV Robotic Surgery Institute, Aalst, Belgium, under the supervision of Prof. Alexandre Mottrie. Dr. Gandaglia has written and coauthored more than 220 peer-reviewed journal articles (PubMed) and his H-Index is 27 (Scopus). He serves as Reviewer for the main urologic journals and in the year 2015 he was selected as Reviewer of the Year by European Urology. Dr. Gandaglia is a member of the EAU Young Academic Urologists Working Party – Prostate Cancer since March 2016. Moreover, Dr. Gandaglia is a member of the Scientific Committee of the Italian Society of Urology (SIU). His main clinical and research interests are focused on prostate cancer, benign prostatic enlargement and bladder cancer with a particular focus on minimally invasive techniques and robotic surgery.

See COI

Paolo Gontero

Paolo Gontero

University of Piemonte Orientale, Urology

Novara, Italy

Disease area: Prostate cancer

Biography:
Paolo Gontero is Associate Professor of Urology at the University of Studies of Torino, Division of Urology, San Giovanni Battista Hospital, Torino, Italy. He is currently Director of a Second Level Master Degree Course in Prostate Oncology at the University of Torino. His main clinical interests are Oncology Urology Surgery, Laparoscopic and Robotic kidney and prostate oncological surgery and Reconstructive Urology. He has authored and co-authored more than 150 publications on international journals. His main research interests pertains the development of new treatment modalities for non-muscle invasive bladder cancer and prostate cancer. He is Scientific Director of the “Torino Prostate Project”, a multidisciplinary clinical and research working group in the field of prostate cancer. He is involved in international trials and working groups on the development of new diagnostic and therapeutic modalities for prostate cancer and on the assessment of surgery in high risk prostate cancer. He is chairmen of the Course on Small Renal Masses at the European School of Urology and holds active membership with EORTC-GU, ISSECAM-EMPACT and eGUS. He has co-authored several book chapters and edited several books, including the latest Problem Based Urology, Springer 2013, awarded by the BMA Book Award as highly commended n surgical specialties.

See COI

Alexander Govorov

Alexander Govorov

Moscow State Medical Stomatological University, Urology

Moscow, Russia

Disease area: Prostate cancer

Biography:
After graduating from Medical School in 1998, Alexander Govorov started his residency in Urology at the Department of Urology of MSMSU in Russia. In 2001 he did a Clinical Fellowship with Prof. L. Boccon-Gibod at the Department of Urology of the Bichat Hospital in Paris. In 2002 he obtained his PhD from MSMSU. He accepted a position of Associate Professor of Urology at the Urology Department of the Moscow State University of Medicine and Dentistry (Chairman - Prof. D. Pushkar) in 2003, and became Professor of Urology in 2017. He is board certified for Urology and Oncology. Dr. Govorov is a member of the EAU, AUA, SIU and the Russian Associations of Urology and Oncology and was a Board Member of the European Society of Oncological Urology (ESOU) from 2006 to 2017. In 2017-2018 – EAU Prostate Cancer Guidelines panel member. In 2006 he has won the Russian award for “The valuable contribution to Russian Urology”. Alexander Govorov’s primary clinical interest concentrates on operative and conservative uro-oncology, and particulary on prostate biopsy and minimally-invasive treatment of prostate cancer. In 2003, he was the first HIFU specialist in Russia and in 2010 he performed the first cryoablation of the prostate in Russia. He has published in several medical journals, wrote chapters of books, participated in many academic and clinical trials and he presented at numerous national and international congresses.

See COI

Charlotte H Graugaard-Jensen

Charlotte H Graugaard-Jensen

Aarhus University Hospital

Aarhus, Denmark

Disease area: Lower Urinary Tract Dysfunction

Biography:
Dr. Graugaard-Jensen is Associate Professor of Urology at the University of Aarhus, Denmark. She studied medicine in Aarhus, where she completed her PhD thesis in 2008 on diurnal regulation of urine production. She conducted her residency in Viborg and Aarhus from 2008-2014, and is now working primarily on functional urology in the pelvic floor section at the Department of Urology, Aarhus University Hospital. Dr. Graugaard-Jensen is an active member of the Danish Urological Association and The Danish Urogynecologic association, in which she has been the treasurer for six years (2010-2016). She is chairwoman of the Nordic group on Lower Urinary Tract Dysfunction (2016-). She participates in a Danish Expert group set by the Health authorities to make a National Recommendation list/guideline to GPs treating lower urinary tract dysfunction. In 2016 she was appointed to the Regional Committee on Health Research ethics. Dr. Graugaard-Jensen has published 10 original scientific articles and 5 book chapters.

See COI

Alexander Haese

Alexander Haese

Martini-Klinik Prostate Cancer Center, University Clinic Eppendorf, Urology

Hamburg, Germany

Disease area: Prostate cancer

Biography:
Still to be added

See COI

Karin Haustermans

Karin Haustermans

University Hospital Gasthuisberg, Radiation Oncology

Leuven, Belgium

Disease area: Prostate cancer

Biography:
Karin Haustermans graduated in 1987 as MD at the KU Leuven in Belgium. In 1993, she completed her training and qualification in Radiation Oncology. After a research fellowship at the Laboratory of Experimental Radiotherapy at the KU Leuven, she obtained her PhD in Medical Sciences for which she received in 1996 the ESTRO-VARIAN Clinical Research Award. Thereafter she spent four years as a staff member at the Netherlands Cancer Institute in Amsterdam. Currently, Karin Haustermans is Chair of the Department of Radiation Oncology at the Leuven Cancer Institute of the University Hospital Gasthuisberg (Belgium) and a Full Professor at the KU Leuven. She is specialized in GI and GU oncology and has a part time research appointment as a Fundamental, Clinical Researcher that is sponsored by the Research Foundation – Flanders. She is also a member of several (inter)national scientific organizations. From 2006 to 2009 she held the Chair of the EORTC Radiation Oncology Group and held the Chair of the Quality Assurance Committee of EORTC from 2009 till the end of 2015. She is also heavily involved in the Belgian Cancer Registry as a member of the board and Chair of the Coordination Council. From 2009-2012, she presented Belgium in the Scientific Council of the International Agency for Research on Cancer (IARC). Apart from her clinical and educational activities, she is running a translational research team both in the clinic as well as in the Laboratory of Experimental Radiotherapy at the KU Leuven. Her current research focuses on early response prediction by means of molecular biomarkers and functional imaging in prostate and rectal adenocarcinomas. She is author or co-author of more than 160 peer-reviewed international publications and is promotor of 6 PhD theses. She is also holder of the VARIAN Chair in Radiobiology at the KU Leuven and is principal investigator on several research grants. In 2010 she was awarded with the ESTRO Breur gold medal for her achievements in research.

See COI

Simon Hawlina

Simon Hawlina

MD Medicina, Urology

Ljubliana, Slovenia

Disease area: Lower Urinary Tract Dysfunction

Biography:
Asist. Prof. Simon Hawlina passed his internship examination in Portugal in 2002. He worked as a medical doctor in Papua New Guinea from May to September 2003 and is a Urology Consultant since 2010. He completed his sub-specialization in laparoscopy under Prof. Renaud Bollens in Belgium in 2014 and his sub-specialization in robotic & laparoscopic surgery under Prof. Justin Vale in England in 2016. In 2018, he received his licence to work with the daVinci Xi - console as a surgeon. He is well-trained in open and laparoscopic surgery and diagnostic procedures in urology. He currently works as an assistant professor at the Medical Faculty of Ljubljana. He is also the leader of a research project team in the Clinical Centre Ljubljana and part of several other research project teams there. He is the director of the Robotic Assisted Laparoscopy Devision at the University Clinical Centre Ljubljana as of 2018. He received the Karl Storz Third prize: “Complications of en-block resection of bladder tumors with bipolar hook cutting electrode” in 2016.

See COI

John Heesakkers

John Heesakkers

University Medical Centre Nijmegen, Urology

Nijmegen, Netherlands

Disease area: Lower Urinary Tract Dysfunction

Biography:
John Heesakkers studied Medicine at the Radboud University of Nijmegen. He started his training in Urology in 1993 at the University Hospital Maastricht. In 1997 he successfully defended his thesis titled: ‘Dynamic Urinary Graciloplasty’ at the University of Maastricht. Since 2000 he is a full time staff urologist at the Department of Urology of the Radboud UMC and consultant at the Rehabilitation Clinic St Maarten in Nijmegen, the Netherlands. He is heading the Unit of Functional Urology and Neurourology. He chairs the Society of Functional and Reconstructive Urology, a body of the Dutch Association of Urology. John Heesakkers is an active member of the AUA, EAU, ICS and SUFU. He is a faculty member of the European School of Urology and of the Scientific Congres Organization of the EAU. Since 2008 he is a principal investigator for the Nijmegen Centre for Molecular Life Sciences. He is reviewer of several major Urologic Scientific journals. He is the author of more than 125 peer-reviewed papers and more than 10 book-chapters and books on urological topics.

See COI

Aino Fianu Jonasson

Aino Fianu Jonasson

Karolinska University Hospital Huddinge, Urogynaecology

Stockholm, Sweden

Disease area: Lower Urinary Tract Dysfunction

Biography:
Aino Fianu Jonasson specialised in urogynaecology and is responsible for the Women’s Health Department at the Karolinska University Hospital Huddinge. She was registered as a physician with the National Board of Health on 21 February 1986 and became a specialist in Obstetrics and Gynaecology on 30 September 1990. She has been director of studies and was responsible for teaching medical students from 1996 until 2009. She has also been training junior doctors and undertaking clinical research. Aino Fianu Jonasson was awarded the KI’s pedagogical price in 2006 for excellent leadership and outstanding skills in developing the medical educational programs. Her research in women’s health are: treatment of postmenopausal women with urogenital atrophy, female urinary incontinence, overactive bladder and nocturia.

See COI

Vincent Khoo

Vincent Khoo

The Royal Marsden NHS Foundation Trust, Radiotherapy

London, United Kingdom

Disease area: Prostate cancer

Biography:
Vincent Khoo is a Clinical Oncologist at Royal Marsden Hospital, Honorary Consultant at St George’s Hospital and Honorary Senior Lecturer at Institute of Cancer Research, London University. He was previously Head of Department of Clinical Oncology Royal Marsden. He is Adjunct Professor, Department of Medical Imaging and Radiation, Monash University and Honorary Associate Professor, Department of Medicine, Melbourne University and Austin Health. He specialises in urological cancers with interests in systemic Clinical Trials, combination treatments, multi-modality imaging, and technical radiotherapy from stereotactic to image guided intensity modulated and adaptive radiotherapy. He has published over 200 papers. He is member of several national/international committees including UK NCRI Clinical-Translational Radiotherapy, UK NCRN Prostate, Penile, and Kidney Clinical Studies Groups, ESTRO, ECCO.

See COI

Paul Kil

Paul Kil

St. Elisabeth Hospital, Urology

Tilburg, Netherlands

Disease area: Prostate cancer

Biography:
To be added

See COI

Matej Knezevic

Matej Knezevic

General Hospital Dr.Josip Bencevic, Urology

Slavonski Brod, Croatia

Disease area: Lower Urinary Tract Dysfunction

Biography:
Matej Knezevic is an urology specialist working in Clinical Hospital Center 'Sestre milosrdnice' in Zagreb, Coratia. He is sub-specialized in the field of urolithiasis. Dr. Knezevic's scientific interest is the exploration of new technologies and their application in surgery. Among other projects, he is coordinating the team for research of three-dimensional printing technologies in urology.

See COI

Angus MacCormick

Angus MacCormick

Taunton & Somerset NHS Foundation Trust, Urology

Taunton, United Kingdom

Disease area: Lower Urinary Tract Dysfunction

Biography:
Dr. MacCormick has been directly involved in the management of patients with prostate disease for the past 20 years. This includes the assessment, investigation and treatment of patients with lower urinary tract symptoms attributed to bladder outflow obstruction as a result of benign prostatic enlargement. He is also actively involved in the management of both male and female patients with symptoms suggestive of bladder over activity and/or nocturia, including nocturnal frequency, nocturnal polyuria and global poyuria. Prostate Cancer is foremost in the minds of men. This condition is a particular interest of Dr. MacCormick. He is actively involved in the initial assessment, diagnostic investigation and treatment of men who have been diagnosed with prostate cancer. This includes undertaking MRI cognitive Trans Rectal Ultrasound Guided Prostate Biopsies, systematic and targeted and also Trans-perineal prostate Biopsies. He also manages their lower urinary tract symptoms and sexual dysfunction post treatment.

See COI

Stefan Machtens

Stefan Machtens

Marien-Krankenhaus, Urology

Bergisch Gladbach, Germany

Disease area: Prostate cancer

Biography:
Dr. Stefan Machtens is head of the department of urology and pediatric urology at Marienkrankenhaus Bergisch Gladbach, an academic teaching hospital of Cologne University. After his university education in Pecs (Hungary), Bochum and Cologne he graduated in medicine in 1994. After short-term stays in St.George Hosspital in Sydney/Australia and St.Joseph Hospital in Atlanta/USA he finished his medical education at the department of surgery at Knappschafts-Krankenhaus in Dortmund Brackel. Dr.Machtens received his urologist specialist training at Hannover Medical School under Prof. Udo Jonas. He passed his board exam in 1999. Since 2002 he worked as senior staff member at Hannover Medical School. In between 2005 to 2006 he became vice chair at the University Department at Hannover Medical School. In 2003 he received his degree as „Medical Hospital Manager“ after studies at the Fachhochschule Hannover. In 2005 he specialized in „Specialized urologic Surgery“. In 2006 he qualified with the additional qualification „Andrology“ and in 2009 in „Medical Tumor Therapy“. He is member of several national and international urological societies. Since 2007 he is member of the German S3-Guideline Panel for prostate cancer. Since 2008 he is member of the EAU/ESTRO Teaching Staff in „Prostate Brachytherapy“. He has been the Managing Editor of The World Journal of Urology in between 1999-2005. Dr. Machtens has been main investigator in multiple phase I-III uro-oncological trials. Dr. Machtens has presented more than 350 invited lectures. He has published more than 90 peer-reviewed articles as author and co-author. He has published 7 books. Dr. Machtens received six national and international scientific awards on the field of uro-oncology and urologic physiology.

See COI

Xavier Maldonado

Xavier Maldonado

University Hospital Vall d'Hebron, Radiation Oncology

Barcelona, Spain

Disease area: Prostate cancer

Biography:
Dr Maldonado works as Radiation Oncologist at the Hospital Universitari de la Vall d’Hebron, Barcelona, Spain, He is a member of several national and international associations as well as board member of the G.I.C.O.R. (Spanish Group for Investigation in Radiation Oncology) He is a fellow of the Spanish School in Radiation Oncology and he has chaired several times the prostate cancer courses and genitourinary oncologic meetings. He is also a reviewer of the main Radiation Oncology journals. He is author and co-author of more than 50 papers published in peer reviewed, indexed Journals. His main clinical interest is urological oncology, where he conducted several clinical trials. He is actually focused in the high risk prostate cancer tumors and in the IGRT (Image Guided Radiation Therapy) quality programs. He is the responsible of the Urological tumors in the Radiation Oncology department.

See COI

Christophe Massard

Christophe Massard

Gustave Roussy Institute, Medical Oncology

Villejuif, France

Disease area: Prostate cancer

Biography:
Christophe Massard (MD, PhD), Medical Oncologist, is Chair of the Drug Development Department (DITEP) at Gustave Roussy, Villejuif, France. He is Consultant Medical Oncologist and full time cancer specialist at Gustave Roussy, half time at the Drug Development department (DDD) and joined the faculty in 2006. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a special interest in Genito urinary cancer and Central Nervous System tumour. Dr Massard received his medical degree from PARIS XI University in 2006, and he got a MSc and PhD from PARIS XI University in 2013. He completed his residency training in Paris Hospital, followed by his fellowship in Medical Oncology at Gustave Roussy. He is board certified in Medical Oncology. He did a post-doctoral fellowship in Prof DeBono’s lab at the Royal Marsden Hospital of London and Institute of Cancer Research (London). Dr Massard is member of ESMO, ASCO, AACR. Over the last 5 years, he was the principal investigators of 15 phase I trials, 1 phase II trial (prostate cancer), and sub investigator of more than 80 clinical trials (phase 1 trials and GU cancers). He is also involved in translational research aspects related to Medical Oncology Precision Medicine(MOSCATO, MATCH R and PETRUS program). Dr Massard has contributed to over 180 peer-reviewed publications, including publications in European Urology, Annals of Oncology and Journal of Clinical Oncology. He is also a member of the editorial boards of Bulletin du Cancer, Investigational New Drugs and European Journal of Cancer. Research axes: early clinical trials, precision medicine, GU cancers (prostate cancer, bladder cancer and testis), glioma, and circulating biomarkers.

See COI

Axel Merseburger

Axel Merseburger

University Hospital Schleswig-Holstein, Urology

Lübeck, Germany

Disease area: Prostate cancer

Biography:
Axel Merseburger is Professor of Urology and Chairman of the Department of Urology at University Hospital Schleswig Holstein, Campus Lübeck, Germany. After graduating from Hannover Medical School in 2002, he carried out a residency in surgery and urology at the Eberhard Karls University, in Tübingen, followed by a research fellowship at the Miller School of Medicine, Miami, USA (2006). He became Associate Professor in 2009 and full Professor in 2012 at Hannover Medical School. Professor Merseburger is a member of various uro-oncology organisations and serves as an advisor for the European Association of Urology (EAU) Guideline Group for Renal Cancer and was the Chairman of the EAU Guideline Group for Lasers and Technologies. He acts as reviewer and editorial board member for several urology and oncology indexed journals and is associate editor of the World Journal of Urology and editor of the Advanced Prostate Cancer Resource Centre. Professor Merseburger’s research activity encompasses both molecular and clinical aspects of uro-oncology, with specific interest in biomarkers and prognostic factors for prostate cancer, renal cell carcinoma and transitional cell carcinoma. He has authored and co-authored >200 peer-reviewed articles and he is the principal investigator in multiple phase II and III clinical trials in Germany.

See COI

Nele Michels

Nele Michels

University of Antwerp, General Practice

Wilrijk, Belgium

Disease area: Lower Urinary Tract Dysfunction

Biography:
Professor Nele Michels M.D, Ph.D. is general practitioner at a group practice in Antwerp, Belgium, and assistant professor at the Faculty of Medicine and Health Sciences, University of Antwerp (Ph.D. thesis (2012) ‘Portfolio learning and assessing at the workplace: development, reliability and validity’). She is educational coordinator and vice-director of the Educational Committee General Practice at the Centre for General Practice, Antwerp and co-coordinator of the Skills Lab at the Faculty of Medicine. For the Flemish Interuniversity Centre for the Education of General Practitioners she is director of the Steering Group Workplace Learning and a member of the Steering Group Curriculum & Assessment. Board Member of the Educational Council at the Faculty of Medicine and Health Sciences and Board Member of the Educational Council at the University of Antwerp. She is an active member of the Scientific Committee of the Dutch-Flemish Society of Medical Education and EURACT representative council member, chair of the Specialty Training Committee. Focus of research is medical education, workplace learning, competence-based education, resilience, and capacity building in GP. She has both national and international publications and is promotor and co-promotor of national and international research projects (e.g. VLIR-UOS TEAM project on intercultural competences, Loja - Ecuador).

See COI

Nicolas Mottet

Nicolas Mottet

University Hospital St. Etienne, Urology

Saint-Etienne, France

Disease area: Prostate cancer

Biography:
Professor Nicolas Mottet is head of the department of Urology at Centre Hospitalier Universitaire in Saint-Etienne, France and Professor of Surgery at the Jean Monnet University, Saint-Etienne, France. Professor Mottet is board certified in surgery, urology and medical oncology in France. He obtained his MD and his PhD from University Montpellier I. Professor Mottet serves as Chairman of the European Association of Urology Working Group on Prostate Cancer Guidelines, as a board member of the Urology Group for the French Anti-Cancer Centre Federation, and as a member of the International Society of Geriatric Oncology Prostate Cancer Guidelines board. He is also a member of the American Urological Association, the American Society of Clinical Oncology, the European Society for Medical Oncology and the French Urological Association, where he served as Coordinator for the Testis and Penile Cancer Subgroup between 2000 and 2008. He is also a member of the New York Academy of Science. Professor Mottet has published over 160 peer reviewed papers, mainly on urologic oncology and prostatic disorders, and has made numerous presentations and lectures. He is an editorial board member of the European Urology Journal and a reviewer of more than a dozen journals, including the New England Journal of Medicine. He is on the scientific advisory board of several pharmaceutical and biotech companies in urology and oncology drug development and clinical trials and has coordinated or participated to more than 40 clinical studies. Professor Mottet has received several peer reviewed grants and is currently coordinating studies on prostate and bladder cancer.

See COI

Alex Mottrie

Alex Mottrie

OLV Hospital, Urology

Aalst, Belgium

Disease area: Prostate cancer

Biography:
Alexandre Mottrie graduated in 1988 from the School of Medicine at the Catholic University of Leuven, Belgium. He completed his residency in 1994 at the Johannes Gutenberg University of Mainz, Germany where he was a staff member till 1996. At present, he is a urologist at the O.L.V. – Clinic in Aalst. His major urological interests are urological oncology and minimal invasive surgery. At his department, he developed laparoscopic and robotic surgery to become training centre in this field. He has authored multiple scientific papers and organised several international congresses in these fields. Dr. Mottrie is Scientific Director of the European Robotic Urology Symposium (ERUS).

See COI

Sandra Nad

Sandra Nad

University Hospital Centre, Urology

Zagreb, Croatia

Disease area: Lower Urinary Tract Dysfunction

Biography:
To be added

See COI

Matthias Oelke

Matthias Oelke

St. Antonius-Hospital, Urology

Gronau, Germany

Disease area: Lower Urinary Tract Dysfunction

Biography:
Matthias Oelke is assistant medical director and the head of the study & science center of the Department of Urology at the St. Antonius Hospital in Gronau, Germany and associate professor of urology at the Hannover Medical School, Hannover, Germany. He primarily focuses on Functional & Reconstructive Urology as well as on Endourology. Dr. Oelke studied medicine in Hannover, Germany where he also conducted his residency in the Department of Urology from 1996 to 2001. In 2003, he passed the examination of the European Board of Urology (Part I). In 2004, Dr. Oelke completed his German doctoral thesis with summa cum laude and, in the same year, he joined the Department of Urology at the Academic Medical Centre in Amsterdam, where he worked as Section Head of Functional & Reconstructive Urology. In 2005, Dr. Oelke completed the Examination of the European Board of Urology (Part II) and was appointed as Fellow of the European Board of Urology, FEBU. Dr. Oelke returned to the Hannover Medical School in Germany in 2008 where he became Vice-Chairman and Associate Professor in 2010. Dr. Oelke successfully defended his international PhD-thesis in Amsterdam in June 2016. He worked at the University of Maastricht, the Netherlands in the year 2017 and changed to the St. Antonius Hospital in Gronau, Germany in 2018. Dr. Oelke is an active member in many societies including the European Association of Urology (EAU), International Continence Society (ICS), International Consultation on Incontinence-Research Society (ICI-RS), Dutch Society of Urology (NVU), the German Society of Urology (DGU), German League of Urologists (BDU), and the German Society of University Teachers. He was chairman of the ‘EAU Guidelines on Male LUTS’ from 2004 to 2012 and panel member until 2014. Dr. Oelke has been member of the DGU ‘Expert Group on Functional Urology’ since 2009. Additionally, Dr. Oelke has been member of the DGU ‘Expert Group on BPH’ since 2001 and was the chairman of this group from 2015 to 2017. He joined the ‘Standardization Steering Committee’ of the ICS in 2017. He was awarded with 16 national or international prizes and received three research grants. Dr. Oelke is a reviewer of more than 20 medical journals, has authored 90 original scientific articles, 99 review articles and 35 book chapters, and published 4 books.

See COI

Aurelius Omlin

Aurelius Omlin

Kantonsspital St. Gallen, Medical Oncology

St. Gallen, Switzerland

Disease area: Prostate cancer

Biography:
Dr Omlin is Medical Oncologist at Kantonsspital St. Gallen in Switzerland During his career, Dr Omlin has been involved in early clinical trials (phase I and II), translational research and genitourinary oncology. In recent years, he has been involved in several trials exploring the use of enzalutamide, carboplatin and abiraterone in prostate cancer Dr Omlin received an American Society of Clinical Oncology award in 2013 and is a member of the European Society for Medical Oncology and Swiss Working Group on Clinical Cancer Research

See COI

Piet Ost

Piet Ost

Ghent University Hospital, Radiation Oncology

Ghent, Belgium

Disease area: Prostate cancer

Biography:
Prof. Dr. Piet Ost works as Radiation Oncologist at Ghent University Hospital, Ghent, Belgium. He is a member of several national and international associations and is vice chairmain of the EAU Young Academic Urologists Prostate Cancer Working Party. He is author and co-author of several papers published in peer reviewed, indexed journals. His clinical and research interests are urological oncology with a specific focus on postoperative prostate cancer radiotherapy and metastasis-directed therapy for oligometastatic prostate cancer. More broadly he implemented stereotactic body radiotherapy (SBRT) for oligometastatic solid tumors at his department and developed a research interest in the combination of SBRT with immunomodulatory agents such as anti-CTLA4 and anti-pd1 antibodies.

See COI

Bradley Pieters

Bradley Pieters

Academic Medical Center, Radiation Oncology

Amsterdam, Netherlands

Disease area: Prostate cancer

Biography:
Bradley R. Pieters, MD, PhD, is Head of the Brachytherapy department at the Amsterdam University Medical Centers (location AMC), The Netherlands. Dr. Pieters is the Course Director of the European Society for Therapeutic Radiology and Oncology (ESTRO) School for the Comprehensive and Practical Brachytherapy course and chair of the GEC-ESTRO Committee. Dr. Pieters was trained in Radiation Oncology at the Radboud University Hospital in Nijmegen, The Netherlands, and received his medical degree in 1990. He completed his residency in radiotherapy at Academic Hospital Nijmegen, The Netherlands. Dr. Pieters then completed a brachytherapy fellowship at the Daniel den Hoed clinic in Rotterdam and L'Institut Gustav-Roussy in Villejuif, France. His brachytherapy training was completed at the Academic Medical Center in Amsterdam. Dr. Pieters received his MSc in epidemiology in 2006 and his PhD in 2010 after defending his thesis “Pulsed-dose rate brachytherapy in prostate cancer.” Dr. Pieters’ main field of interest is general brachytherapy with an emphasis on urologic brachytherapy, gynecologic brachytherapy, and pediatric brachytherapy. Dr. Pieters is currently the Principal Investigator of the PROBACH trial (Randomized Phase 3 Study on the Assessment of Late Toxicity by Comparing IMRT High Dose External Beam Radiotherapy Only With External Beam Radiotherapy Combined With HDR or PDR Brachytherapy in Patients With Intermediate/High Risk Prostate Cancer) and POWER trial (Randomized Trial to Evaluate Erectile Dysfunction after Whole or Partial Gland Prostate Brachytherapy. He is also working on the following research projects: multimodality dose summation assessment and evaluation for cervical cancer; quantification of treatment-induced growth disruption using 3D photography in children with (orbital) rhabdomyosarcoma; ICT-based innovations in the battle against cancer – next-generation patient-tailored brachytherapy cancer treatment planning. Dr. Pieters is co-editor of the Journal of Contemporary Brachytherapy and serves as a referee for the following journals: Radiotherapy and Oncology; International Journal of Radiation Oncology Biology and Physics; Brachytherapy; the Journal of Contemporary Brachytherapy; Physics and Imaging in Radiation Oncology.

See COI

Guillaume Ploussard

Guillaume Ploussard

Saint Jean Languedoc Hospital and Institut Universitaire du Cancer, Urology

Toulouse, France

Disease area: Prostate cancer

Biography:
Guillaume Ploussard (MD, PhD) is working as uro-oncologist in Toulouse, France, at Saint-Jean Languedoc Hospital and Institut Universitaire du Cancer - Oncopole. After Medical School at the University of Paris, he completed during his training a robotics fellowship at the Department of Urology, McGill University in Canada. His main interests include basic (biomarkers in prostate cancer) and clinical (focal therapy, minimally invasive techniques, fusion biopsies) research that has been funded by research grants in uro-oncology. Guillaume Ploussard is managing editor of World Journal of Urology, section editor of European Urology Today, member of the sub-committee at the EAU section of Oncological Urology, chairman of the EAU working group on prostate cancer and member of the French Cancerology Committe (CC-AFU). He has published more than 160 articles in peer-reviewed journals and received multiple national and international awards for his work.

See COI

Javier Puente

Javier Puente

Hospital Universitario Clinicos San Carlos, Medical Oncology

Madrid, Spain

Disease area: Prostate cancer

Biography:
Javier Puente was born in Madrid (Spain) in 1977. He received his medical degree in 2001 at the Complutense University of Madrid (Spain) followed by his fellowship in 2002. He received his Advanced Study Accreditation (DEA) degree at Complutense University of Madrid in 2004 while completing the medical oncology program at Hospital Clinico San Carlos, Madrid, under the direction of Professor Eduardo Díaz-Rubio from 2002-2006. Dr. Puente earns his Doctorate in Medicine (PhD) with a mention of “Cum Laude” in 2007 followed by a special prize of doctorate in 2009 at Complutense University of Madrid (Spain). Dr. Puente served as resident in the Medical Oncology Department at Hospital Clinico San Carlos from 2002-2006 at which point he became one of the clinical lead and researcher in the Thoracic, Urinary and Melanoma Cancer Unit. Today, he is the Director of the Institute of Oncology at that hospital. From 2006-2010 he was also Honorific Professor at the Complutense University of Madrid (Spain) where he was named Associate Professor of Medicine in 2011. In 2009, Dr. Puente was named National Medical Advisor at Asociación Española contra el Cáncer (AECC) and Staff Researcher of Clinical Trials Spanish Plattform (CAIBER) at Hospital Clinico San Carlos. He served as a member of the Scientific Board of the Spanish Medical Oncology Society (SEOM) from 2013-2015 and joined the Local Ethics Committee at Hospital Clinico San Carlos in 2015 where he continues to serve as a member. Also, in that year, he became a clinical associated with the Centro Nacional de Investigaciones Oncológicas (CNIO). In addition to SEOM and CNIO, Dr. Puente is also a member of the Spanish Lung Cancer Group (GECP), since 2009, the Spanish Oncology Genitourinary Group (SOGUG), since 2009, the Spanish Group of Orphan and Rare Tumors (GETHI) ,since 2009, and he is a member of the American Cancer Society (ASCO) and European Society of Clinical Oncology (ESMO). Dr Puente has been involved with multiple independent research projects, multiple publications and presented at countless national and international conferences.

See COI

Jon Rees

Jon Rees

Backwell & Nailsea Medical Group, General Practice

North Somerset, United Kingdom

Disease area: Lower Urinary Tract Dysfunction

Biography:
Jon Rees trained in Urology in Taunton and became a Member of the Royal College of Surgeons in 1999. He then spent 3 years completing research into the impact of prostate cancer on the quality of life of men and their partners, and was awarded his MD thesis in 2003. In 2004 he switched to General Practice and is now a partner at Tyntesfield Medical Group in North Somerset. He continues to work in Urology, providing a primary care diagnostic urology service to 3 CCG's, including a community based LUTS, Haematuria and raised PSA one-stop service. He is a founding director of Shire Health, providing Urology Advice & Guidance services to 2 CCG’s and running a Community Urology service in Gloucestershire. He was a member of the Guideline Development Group for the NICE 'Lower Urinary Tract Symptoms in men' Clinical Guideline, published in 2010 and an Expert Advisor to the NICE Quality Standard for Prostate Cancer in 2015. He is deputy editor of ‘Trends in Urology and Men’s Health’ (www.trendsinurology.com) and involved extensively in educating his fellow GP’s about Urology, particularly through the Prostate Cancer UK Masterclasses. He is currently chair of the educational advisory group for Prostate Cancer UK, previously chair of the ‘Prostatitis Expert Reference Group’ at Prostate Cancer UK and a member of the Clinical Advisory Board for ‘Tackle Prostate Cancer (formerly known as the Prostate Cancer Support Federation). In 2014, he founded (and now chairs) the Primary Care Urology Society – for GP’s with an interest in Urology or who wish to develop skills in this area. (www.primarycareurologysociety.org) In June 2015 he became a trustee of the charity ‘Action on Bladder Cancer UK’. In his ‘spare time’, he is an active trustee of the Health Improvement Project Zanzibar (www.hipz.org.uk) – a small UK based charity which runs 2 district hospitals on the island of Zanzibar, providing essential healthcare for over 250,000 people.

See COI

Mesut Remzi

Mesut Remzi

Regional Hospital of Weinviertel-Korneuburg, Urology

Korneuburg, Austria

Disease area: Prostate cancer

Biography:
Mesut Remzi did his residency and his “Habilitation” at the Medical University of Vienna. Recently he became vice chairman at the Landesklinikum Korneuburg. His clinical activity is uro-oncology, mainly kidney tumors, prostate cancer and upper urinary tract urothelial carcinoma. He is specialised in laparoscopic surgery. Right now he is the primary investigator for an international, multicenter collaborative trial on organ-sparing surgery on upper urinary tract urothelial carcinoma (OSS-UTUC). He is (co)-author of more than one hundred peer-reviewed original articles. He was reviewer of the moth for European Urology and is member as Editor at glace for European Urology, Editor in the World Journal of Urology and reviewer for many urologic journals.

Maria Ribal

Maria Ribal

University Hospital Clinic Barcelona, Urology

Barcelona, Spain

Disease area: Prostate cancer

Biography:
Maria J. Ribal received her medical degree in 1994, followed by her PhD in 2002, both at the University of Barcelona. She attended as Visiting Clinician at Mayo Clinic in Rochester (USA) in 2002. Fellow in Laparoscopic Surgery at the University College London Hospital (UCLH) from June till December 2006. She has been member at the Oncology Unit of the Department of Urology at Fundacio Puigvert (2002-2005). Since February 2005, she is member of the Department of Urology at the University Hospital Clinic of Barcelona. Currently, she is Associated Professor of Surgery at the University of Barcelona. From December 2011 she is the Head of the Uro-Oncology Unit at Hospital Clinic, that comprises a multidisciplinary team: urologists, medical oncologists, radiation oncologists, pathologists, radiologists, nutritionists, nurses and all those involved in the manage and therapy of uro-oncological malignancies. Her main interest is Uro-Oncology and renal transplantation. She is actively involved in translational research in the field of urological malignancies and actively involved in clinical research at the Uro-Oncology Unit She is the author of over hundred international and national publications, 10 book chapters, and > 300 invited lectures at conferences and courses. She is an active member of European Association of Urology (EAU): Member of the Muscle Invasive and Metastatic Bladder Cancer Guidelines Group of the EAU since 2006 and vice-chair since 2018, Member of the EAU section of Uro-Technology (ESUT) since 2010. Board member of the European Urological Scholarship Programme of the EAU (EUSP) since April 2012 and Board Member of the EAU Guidelines Office since January 2016. In 2009, during the EAU Annual Meeting held in Stockholm, she received the Crystal Matula award, a prestigious prize granted to a young promising European urological academician.

See COI

Martin Spahn

Martin Spahn

University Hospital Bern, Urology

Bern, Switzerland

Disease area: Prostate cancer

Biography:
Dr Martin Spahn is currently Senior Consultant at the Center of Urology at the Hirslanden Klinik Zürich, Prostate Cancer Center Hirslanden Zürich. He is Prof. of Urology at the university of Essen, Germany. His professional career started in Germany where he was born: he graduated in Medicine in 1993 and specialized in Urology and Surgical Urology in 2001 at the University of Mannheim. In 2007 he was appointed Adjunct Clinical Head at the Department of Urology of the Community Hospital Karslruhe, Germany and from 6/2007 on at the Department of Urology and Pediatric Urology at the University Hospital in Würzburg, Germany where he worked until 2012 before moving to the Inselspital Bern, University Hospital, Bern, Switzerland. Dr Spahn is member of several scientific societies, including AUA, EAU. He serves as member of the Steering Committee of the Genito-Urinary Group of the EORTC since 2013. He is PI (Principal Investigator) of a large translational Research project (SPECTApros), an EORTC Reseach platform. He has published over 100 papers in peer-reviewed journals. Dr Spahn is reviewer for several journals including European Urology, British Medical Journal, Journal of Urology and serves as a grant reviewer for several scientific organisations in europe including Cancer Research UK, German Cancer League and Swiss National Fund. He received several awards for his translational resarch in high risk Prostate Cancer including the Prostate Cancer Research Award of the EAU in 2015 and the Urological Oncology Award of the EAU in 2011.

See COI

Johan Stranne

Johan Stranne

Sahlgrenska University Hospital, Urology

Göteborg, Sweden

Disease area: Prostate cancer

Biography:
Dr. Johan Stranne is an associate professor at the Sahlgrenska Academy, Gothenburg University and a senior consultant at the Department of Urology at the Sahlgrenska University Hospital, Gothenburg, Sweden. He obtained his medical degree from the University of Lund, Sweden in 1997. Following a 2-year internship in Trollhättan, he received his medical licence in 1998. Afterwards, he became a resident at the Department of Urology at the Sahlgrenska University Hospital in Gothenburg. He was accredited as specialist in urology in 2003, and he passed the European Board of Urology specialist exam in Urology (FEBU) in 2004. He has been active as a consultant in urology in the Sahlgrenska University Hospital ever since. Dr. Stranne’s clinical research focuses on treatment of localised prostate cancer with a minimization of side effects. In 2006, he obtained his PhD from the University of Gothenburg with a dissertation about inguinal hernia after urological surgery in males, with specific reference to radical retropubic prostatectomy. He published several peer-reviewed articles on this topic, as well as on robot-assisted radical prostatectomy, PSA-screening, LUTS and ED. Currently, Dr. Stranne is doing research in several clinical studies on prostate cancer and radical prostatectomy, such as the SPCG 15 (RCT of RT + HT vs RP of locally advanced PC), SPCG 17 (active surveillance), the Gothenburg 2 study (PSA-screening) and the LAPPRO-study (prospective comparison RRP vs RALP). Dr. Stranne is member of several national and international urological societies, such as the Scandinavian Prostate Cancer Group (SPCG), European Association of Urology and the Swedish Urological Association.

See COI

Michiel Strijbos

Michiel Strijbos

AZ Klina, Medical Oncology

Antwerp, Belgium

Disease area: Prostate cancer

Biography:
Dr. Michiel Strijbos is a Consultant Medical Oncologist at the AZ Klina hospital in Brasschaat, Antwerp. He was trained at Leuven University in Belgium and the Erasmus University in Rotterdam, The Netherlands, where he graduated in 2004. Between 2004 and 2009, he enrolled in a PhD project focusing on tumor vasculature at the Daniel den Hoed Cancer Center in Rotterdam, for which he was awarded a PhD. Dr. Strijbos received his board certification in Medical Oncology in 2014. In his daily practice, Dr. Strijbos focuses on the research and treatment of genitourinary malignancies, as well as sarcoma. He is currently active in several task forces and committees with regards to GU malignancies and is a principal investigator in several clinical trials in this field. He is also a member of the ESMO GU Faculty, EORTC GU group, and serves as an associate editor for the ESMO Open GU section, and co-authored several book chapters related to GU malignancies.

See COI

Arnoud Templeton

Arnoud Templeton

Kantonsspital St. Gallen, Medical Oncology

St. Gallen, Switzerland

Disease area: Prostate cancer

Biography:
Dr. Arnoud Templeton is a senior consultant at the tumour centre St. Claraspital in Basel, Switzerland, and member of the Faculty of Medicine of the University Basel. He graduated in medicine at the University of Basel and gained his MD in 2003. He completed his medical training in St. Gallen with the Swiss board certification in Internal Medicine. Dr. Templeton also received his oncology specialist training at the Kantonsspital St. Gallen. He attended the Flims Workshop Methods in Clinical Cancer Research in 2008, passed the ESMO exam in 2009 and gained the Swiss Board Certification in Medical Oncology in 2010. He worked as medical advisor for the Swiss Group for Clinical Cancer Research (SAKK) from 2010 to 2012. From 2012 to 2014 he was a clinical research fellow at Princess Margaret Cancer Centre Toronto, Canada, with a focus in GU oncology. His major clinical and research interest is prostate cancer and markers of inflammation. He has been co-investigator in several phase I – III trials and is co-principle investigator of a large multicentre trial conducted in Switzerland and has published more than 90 peer-reviewed articles as author or co-author. Dr. Templeton is a regular reviewer for various oncologic and urologic journals and is a member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the Swiss Group for Clinical Cancer Research (SAKK), and the Swiss Medical Association (FMH).

See COI

Camilla Thellenberg Karlsson

Camilla Thellenberg Karlsson

Umeå University, Oncology

Umeå, Sweden

Disease area: Prostate cancer

Biography:
Dr Camilla Thellenberg Karlsson is a senior consultant at the Department of Oncology, Cancercentrum at Umeå University Hospital and a PhD researcher at the Department of Radiation Sciences, Oncology at Umeå University. She obtained her medical degree from the University of Umeå in 1997 followed by an 2-year internship in Sundsvall to provide for the medical licence in 1998. After that she returned to Umeå and became resident at the Department of Oncology, Cancercentrum at Umeå University Hospital. Following this path she became accredited as a specialist in Oncology 2006 and has ever since worked as a consultant and focused her clinical work on Uro-oncology, mainly Prostate Cancer. The research questions were first focused on genetic epidemiology and her thesis was defended in 2008. After that focus has mainly been on clinical studies trying to improve treatment for both localised and disseminated prostate cancer. She is at present Process leader of Prostate Cancer in the Northern region of Sweden and Head of the Swedish Uro-Oncology Society as well as a board member of the international urological society, Scandinavian Prostate Cancer Group SPCG.

See COI

Derya Tilki

Derya Tilki

University Hospital Hamburg-Eppendorf, Urology

Hamburg, Germany

Disease area: Prostate cancer

Biography:
Dr. Derya Tilki is an Associate Professor of Urology at the Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf in Germany specializing in prostate cancer. Dr. Tilki completed her urology residency training at the Ludwig-Maximilans-University in Munich. She subsequently completed a clinical fellowship in Urologic Oncology at UC Davis in Sacramento. After completion of her training she joined the Faculty at the Martini-Klinik Prostate Cancer Center. Dr. Tilki is on the Editorial Board for European Urology and the British Journal of Urology International. She has published over 200 peer-reviewed articles and 4 book chapters. Dr. Tilki is an Associate Editor of European Urology Focus.

See COI

Bertrand Tombal

Bertrand Tombal

University Hospital Saint-Luc, Urology

Brussels, Belgium

Disease area: Prostate cancer

Biography:
Professor Bertrand Tombal is Chairman of the Division of Urology and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is member of the Belgian Royal Academy of Medicine. He is the Member of the Board of European Organization for Research and Treatment in Cancer (EORTC), the leading European academic research organization in the field of cancer. He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. Professor Tombal obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain. During his PhD, he studied the mechanisms involved in apoptosis of prostate cancer cells and the modulation of apoptosis by growth factors. He completed part of his basic sciences training at Johns Hopkins University, Baltimore, MD, USA. Professor Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the uro-oncology division at the Université catholique de Louvain where he is coordinating several trials in this research area. In addition, Professor Tombal has authored many published papers, books, and book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology thesis award, which he received in 2003. Professor Tombal is also member of Belgium College of Oncology, the Skeletal Care Academy, and member of the Scientific Office of European Association of Urology.

See COI

Levent Türkeri

Levent Türkeri

Academic Hospital, Urooncology

Istanbul, Turkey

Disease area: Prostate cancer

Biography:
Levent Türkeri MD, PhD is a Professor of Urology at Acıbadem University School of Medicine in İstanbul, Turkey. He is a Uro-oncologist with expertise in robotic, laparoscopic and open surgery. His research interest involves molecular aspects of diagnosis and prognostic factors of urological malignancies along with clinical trials. Currently, he is serving as the Board member of Urooncology Association of Turkey, Director of School of Urology and Coordinator of Board of Urology at Society of Urological Surgeons (Turkey) and also actively involved in a number of national and international urological societies such as AUA, EAU, URS, AAEU, ESOU, ESUR, EORTC. Area of Expertise: Urooncology (Prostate Cancer, Bladder Cancer, Kidney Cancer, Testis Cancer), Urologic Surgery (open, laparoscopic, robotic surgery), Molecular Urology

See COI

Frank Van der Aa

Frank Van der Aa

University Hospitals Leuven, Urology

Leuven, Belgium

Disease area: Lower Urinary Tract Dysfunction

Biography:
Frank Van der Aa is adjunct head of clinic in the Department of Urology in the University Hospitals Leuven and staff member of the National MS Center in Melsbroek, both in Belgium. In addition, he is lecturer of the Faculty of Medicine at the Catholic University of Leuven. His special clinical interests are in neuro-urology, male and female incontinence and reconstructive urology. His major research interest include animal models of stress urinary incontinence, interstitial cells, nerve regeneration and stem cell applications. He received his MD in 2001 from the Catholic University of Leuven and obtained his PhD in Medical Sciences in 2007 from the same university. He completed his residency in Urology in 2008 at UZ Gasthuisberg in Leuven. He became Fellow of the European Board of Urology (FEBU) in 2010 and Fellow of the European Board of Sexual Medicine (FECSM) in 2012. He is faculty member of the European School of Urology (ESU) since 2009, Editorial Board member of Neurourology and Neurodynamics since 2011, and member of the Video Congress Committee of the European Association of Urology (EAU) Scientific Congress Office since 2012. He is board member of the EAU section of Female and Functional Urology since 2012 and president of the working group functional urology of the Belgian Association of Urology (BAU).

See COI

Philip Van Kerrebroeck

Philip Van Kerrebroeck

Maastricht University Medical Center, Urology

Maastricht, Netherlands

Disease area: Lower Urinary Tract Dysfunction

Biography:
Philip E.V. Van Kerrebroeck, MD, PhD, MMSc was born in Leuven (Belgium) and obtained the medical degree with distinction from the University of Leuven in 1978. He trained in General Surgery and Urology in Belgium and The Netherlands, and was registered as an urologist in 1984. He received a Master Degree in Medicine from the University of Antwerp (Belgium) in 1992 and a PhD degree in Medical Sciences from the University of Nijmegen (The Netherlands) in 1993. Since 1993 he is Fellow of the European Board of Urology. Philip Van Kerrebroeck has working as an urologist at the Department of Urology of the Radboud University Hospital in Nijmegen and was consultant at the Spinal Cord Unit of the St Maartens Hospital from 1988 till 1996. In 1996 he followed additional training in Neuro-Urology with Professor Tanagho at the USCF in San Francisco, and was appointed as Professor of Neuro-Urology at the University of Maastricht in August 1996. From September 1997 till August 2012, Philip Van Kerrebroeck was Chairman of the Department of Urology in the Maastricht University Hospital Maastricht (MUMC+). Since November 1998 he is Professor of Urology at the University of Maastricht and works as urologist in the Department of Urology and the Pelvic Care Centre of the MUMC+. Professor Van Kerrebroeck is past Board member of the International Continence Society (ICS) and past-chairman of the ICS Standardisation Committee. He is currently member of the History Office of the EAU. Professor Van Kerrebroeck has a broad clinical experience in different forms of lower urinary tract dysfunction in men and women. His research interests are focused on new therapies in Functional Urology such as pharmacotherapy and neuromodulation for voiding dysfunction. Recently he got also involved in the history of Urology with a specific interest in Urological Surgery and Urology in France in the 19th century. Professor Van Kerrebroeck is member of 25 scientific societies and sits on the Editorial Board of 6 scientific journals. In addition, he is reviewer for 7 urological journals. He authored 14 books, 32 book chapters and 312 scientific articles in peer-reviewed journals.

See COI

Jeroen van Moorselaar

Jeroen van Moorselaar

VUmc Cancer Centre Amsterdam, Urology

Amsterdam, Netherlands

Disease area: Prostate cancer

Biography:
Jeroen van Moorselaar studied Medicine at the University of Nijmegen in the Netherlands and obtained his medical degree in June 1987. He continued his career as research fellow in the urological research laboratory of the Urology Department at the University Hospital in Nijmegen where he did his PhD entitled ‘Cytokine Therapy in Experimental Urological Cancer’ in 1991. He was certified as urologist in June 1997. From that time he has worked in the University Hospital in Nijmegen in the Urological Department and in April 1998 he moved to the University Hospital in Utrecht where he worked until August 2005. In September 2005 he became the head of the Urological Outpatient Department at the VU University Medical Centre in Amsterdam where he still works, but since August 2008 in the position of Chairman. In March 2011 he was appointed as Professor of Urology. He is member of various national and international organizations. He is member of the Dutch working party on urological oncological guidelines and is founding member of the Dutch UroOncology Studygroup. Since May 2007 he is board member of the European School of Urology. Furthermore he is Incoming President of the European Board of Urology. He is an active researcher in the field of Urological Oncology. He has published over 180 peer reviewed papers and book chapters.

See COI

Inge van Oort

Inge van Oort

University Medical Centre Radboud, Urology

Nijmegen, Netherlands

Disease area: Prostate cancer

Biography:
Dr. Inge van Oort completed her urological training at het Radboud University Nijmegen Medical Centre, the Netherlands, in 2006. In that same year she started her fellowship in oncological urology and she also became part of the faculty at the Radboud University Nijmegen Medical Centre (chairman: Peter Mulders). In 2008 she was appointed as an oncological urologist and senior staff member. In 2009, she obtained her PhD on the clinical relevance of pathological findings after radical prostatectomy at the department of Urology at the Radboud University Nijmegen Medical Centre. Her main interest in oncological urology is the (surgical) treatment of prostate and bladder cancer. In research she has interests in finding new molecular markers in prostate cancer and in the treatment of castration resistant prostate cancer. She also has been part of several large trials in CRPC (i.e Cougar 301 and 302 (abiraterone), Proselica and compassionate use program (cabazitaxel), Affirm and Previal (enzalutamide), provenge (sipuleucel-T), orteronel. On national level she has been part of several activities at the Dutch Urological Society(DUA). She was the chair of the working group on Oncological Urology (WOU) for 7 years, member of the board of education for residents (CCO), and member of the “Quality of care” group. She is member of the multidisciplinary Dutch guideline group on prostate cancer. At the EAU she’s a member of the EAU Guideline Office- new media group and was part of the Young academic Urologists (prostate cancer group) from 2011-2014. In 2013 she received a grant from the Dutch cancer foundation for a study on Quality of care in prostate cancer treatment and in 2015 a grant from the ZonMW for a study on tumor response markers in combination with drug exposure measurement. Inge M. van Oort is member of national and international urological and oncological associations. She is also reviewer for national and international journals and member of the editorial board of the world journal of Urology.

See COI

Jochen Walz

Jochen Walz

Paoli-Calmettes Institute Cancer Centre, Urology

Marseille, France

Disease area: Prostate cancer

Biography:
Jochen Christoph Walz, MD is the head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre in Marseille, France. He was chairman of the EAU Section of Urological Imaging from 2009 to 2017. Dr. Walz attended the Medical School of the University of Mainz, Germany. He completed his dissertation at the University of Mainz about “Mechanisms of mutagenesis of ultimate geno-toxique substances influenced by homogenate of human erythrocytes”. Afterward, he completed his residency in Urology at the University of Marseille, France and Hamburg, Germany. He is board certified urologist since 2005. He became a research fellow at the Cancer Prognostics and Health Outcomes Unit at the University of Montreal, Canada in 2006-2007 and received his “Habilitation” in 2008 in Urology at the University of Hamburg, Germany. He is specialized in urooncology and urological imaging.

See COI

Thomas Wiegel

Thomas Wiegel

University Hospital Ulm, Radiation oncology

Ulm, Germany

Disease area: Prostate cancer

Biography:
To be added

See COI

Thomas Zilli

Thomas Zilli

University of Geneva, Oncology

Geneva, Switzerland

Disease area: Prostate cancer

Biography:
Dr Zilli is a faculty at Geneva University Hospital, Switzerland, where is working as a senior clinician and vice-chief in the Division of Radiation Oncology. He graduated in Medicine and Surgery in 2004 at University of Udine (Italy) and specialized in Radiation Oncology at the Geneva University Hospital, Switzerland. He completed a 1-year fellowship in prostate brachytherapy at the Centre Hospitalier de l'Université de Montréal (CHUM), Canada. He obtained the Privat-Docent at the Faculty of Medicine of Geneva in 2015 and the Chargé de Cours title in March 2017. He is responsible for the treatment of prostate and genitourinary tumors at Geneva University Hospitals and actively involved since its creation in 2014 in the organization of the Geneva Prostate Cancer center. Main research includes mainly the treatment of prostate cancer patients using modern high-precision radiotherapy techniques including IMRT, VMAT and SBRT as well as the use of molecular imaging in the radiotherapy planning and the treatment of gastrointestinal tumors. He already published 70+ original peer-reviewed articles and he serves as reviewer for different peer-review journals including IJROBP, Radiotherapy and Oncology, Radiation Oncology, Acta Oncologica. He is actively involved in the GFRU (Groupe Francophone de Radiothérapie Urologique) association and active member of the European Organisation for Research and Treatment of Cancer (EORTC) and Swiss Group for Clinical Cancer Research (SAKK).

See COI